Tamoxifen and testolactone in therapy of oligozoospermia: results of a randomized study.

40 patients with oligoasthenozoospermia in infertile marriages were subjected to randomized treatment with 30 mg tamoxifen/day (n = 20), or with 30 mg tamoxifen/day and 150 mg testolactone/day (n = 20), to prevent elevation of estradiol levels during monotherapy with tamoxifen. In both groups there was a significant increase in FSH, LH and testosterone. The elevation of estradiol serum levels was significant (p less than 0.0001) in the tamoxifen group, and not significant in the group with combination therapy. The increase in sperm density was significant in both groups (p less than 0.001; p less than 0.002, respectively), but no differences were seen between both groups. No improvement of the other ejaculate parameters was seen in either groups. The incidence of gravidity was the same under additional testolactone therapy (n = 3).
AuthorsU Maier, G Hienert
JournalEuropean urology (Eur Urol) Vol. 14 Issue 6 Pg. 447-9 ( 1988) ISSN: 0302-2838 [Print] Switzerland
PMID3141194 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Tamoxifen
  • Testosterone
  • Testolactone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Drug Therapy, Combination
  • Follicle Stimulating Hormone (blood)
  • Humans
  • Luteinizing Hormone (blood)
  • Male
  • Oligospermia (drug therapy)
  • Random Allocation
  • Sperm Count (drug effects)
  • Tamoxifen (therapeutic use)
  • Testolactone (therapeutic use)
  • Testosterone (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: